Edinburgh-based business Craneware is a leading player in the transformation of the US healthcare system, offering cloud-delivered SaaS, data solutions, and 340B compliance software.
They reported a 7.4% increase in statutory profit before tax to $25.8 million for the fiscal year ending June 30, 2026 (The Herald). Despite the pre-tax profit increase, the healthcare software provider experienced a very challenging financial year.
Craneware Headline Financial Performance (FY26)
The FY26 financial result fell short of the board’s original expectations. Figures show that despite strong customer engagement and underlying demand, the growth they expected in the second half of the fiscal year failed to materialise.
Sales momentum slowed during H2, even though annual revenue from new sales outside the 340B Shelter programme, a specialised software and service program developed by The Craneware Group, remained at the same level as FY25. That suggests a concentrated weakness, not a business-wide issue.
Many additional challenges arose after the end of the financial year. In July 2026, Craneware disclosed a cyber security incident involving unauthorised access to part of its data environment and data exfiltration. The subsequent investigation found that some employee data and a subset of customer and partner records had been accessed.
The final financial consequences remain unknown. Remediation and legal and regulatory work could continue across several financial periods, meaning Craneware has taken a more cautious approach to FY27 by resetting revenue expectations to around $185 million.
The revised outlook also triggered a sharp market reaction, with share prices falling 24%. Market participants closely watch that volatility, using everything from conventional share dealing to online CFD trading, which involves speculating on the rise or fall of the price of underlying assets.
Stalled Growth in Key US Healthcare Market
340B headwinds largely drove Craneware’s stalled growth. Their 340B products serve US hospitals that participate in the federal 340B drug-pricing programme. The software they developed continued to identify significant 340B opportunities for customers.
Still, operational restrictions and uncertainty meant customers couldn’t convert many of those opportunities into transactions, so expected transaction revenue did not materialise.
Revenue from signed licences for Craneware’s 340B rebate solution was also deferred pending regulatory clarification, further limiting revenue growth.
Craneware had a difficult year despite remaining profitable. Much will now depend on whether regulatory uncertainty in the US 340B market eases and whether Craneware can return to stronger revenue growth without further disruption.
